Bruker Partners with Western Australia to Validate Health Benefits of Soluna™ Apples
Ettlingen, Germany - December 16, 2024 - Bruker, in a pioneering collaboration with the Western
Australia Department of Primary Industries and Regional Development (DPIRD), Murdoch University,
and Fruit West Co-operative, has launched an innovative project to validate the health benefits of the
high polyphenol apple variety ANABP 01, branded as Bravo™ in Australia and Soluna™ internationally.
Supported by Future Food Systems Cooperative Research Centre (CRC) it aims to provide scientific
evidence on the potential health benefits of Soluna™ apples, utilizing state-of-the-art analytical testing
technology, including Nuclear Magnetic Resonance (NMR) and a comprehensive human health study.
This dual-focused initiative will involve the development of new branded and value add products
made from the ANABP 01 apple at the Sustainable Innovative Food Technologies (SIFT) Centre and
the evaluation of human nutrition study at the Australian National Phenome Centre (ANPC). The
development aims at creating apple-derived products with extended shelf-life and preserved bioactive
components. The nutritional study focuses on how the high polyphenol apple variety may impact
cardiovascular disease and diabetes risk factors by measuring changes in cholesterol, blood pressure,
and blood glucose levels over a 20-weeks period. Recruitment is currently open, and the local
community is invited to be part of the study and can register their interest using the link here:
https://bravoapples.com.au/the-apple-study/
“This exciting project will provide invaluable scientific evidence on the potential nutritional and health
benefits of the ANAB01 apple variety in relation to chronic diseases. Additionally, it will produce delicious and healthenhancing value-added apple products for consumers,” said project lead Dr Ruey Leng Loo, Associate Professor in Molecular Nutrition at Murdoch University.
“The project will support Fruit West’s ongoing market strategies to forge new domestic and international
trade avenues for value added ANABP 01 apple products – supporting long term industry growth and profitability,” said Ann Lyster, Chair of Fruit West Cooperative Ltd.
"The ANABP 01 apple is a breakthrough in agricultural innovation, offering enhanced nutritional
value due to its high polyphenol content. This collaboration highlights DPIRD’s dedication to scientific excellence and our commitment to improving community health and the state’s sustainable economic
growth," said Mr. Rohan Prince, Director of Horticulture and Irrigated Agriculture at DPIRD.
“The Future Food Systems CRC is proud to support this project, which holds immense
commercial potential for local industry. By fostering innovation and collaboration, we aim to drive
economic growth and deliver significant benefits to our community” said James Krahe, CEO of Future
Food Systems CRC.
"This project is a testament to our commitment to evidence-based analytical testing innovation. By integrating NMR-based methodologies from our NMR FoodScreener and IVDr platforms, we are ensuring foodquality and consistency while promoting societal health and well-being," said Dr. Joerg Koehler, Senior Director for Cleantech, Industrial and Applied Markets at Bruker.
Looking ahead, the project aims to make significant strides in the fields of food technology and health sciences, with the utilization of advanced technologies. With a completion date set for February 2026, the research will continue to explore the full potential of the ANABP 01 apple. This initiative aims not only to enhance consumer health but also to open new markets and opportunities for apple growers and the food industry.
The Bruker NMR FoodScreener and IVDr is used to validate the health benefits of SolunaTM apples.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new
applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Media Contact
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com